Translational Research Cancer Cente is a USA domiciled entity or foreign entity operating in the USA. The EIN ihas been issued by the IRS
2023-12-31 |
---|
Gross receipts from all sources | USD $ 115,078 |
Net assets / fund balances at end of fiscal year | USD $ 92,233 |
Net assets / fund balances at beginning of fiscal year | USD $ 101,152 |
Total revenue | USD $ 115,078 |
Total of all other expenses | USD $ 123,997 |
Total of all expenses | USD $ 123,997 |
Net assets or fund balances at end of year | USD $ -8,919 |
Revenue from membership dues | USD $ 115,078 |
2022-12-31 |
---|
Gross receipts from all sources | USD $ 95,235 |
Net assets / fund balances at end of fiscal year | USD $ 101,152 |
Net assets / fund balances at beginning of fiscal year | USD $ 65,666 |
Total revenue | USD $ 95,235 |
Total of all other expenses | USD $ 59,749 |
Total of all expenses | USD $ 59,749 |
Net assets or fund balances at end of year | USD $ 35,486 |
The following addresses have been detected as associated with Tax Indentification Number 831794049